[go: up one dir, main page]

KR890009405A - Preparation of Sephamandolnaphate Formulation for Parenteral Use - Google Patents

Preparation of Sephamandolnaphate Formulation for Parenteral Use Download PDF

Info

Publication number
KR890009405A
KR890009405A KR1019870015751A KR870015751A KR890009405A KR 890009405 A KR890009405 A KR 890009405A KR 1019870015751 A KR1019870015751 A KR 1019870015751A KR 870015751 A KR870015751 A KR 870015751A KR 890009405 A KR890009405 A KR 890009405A
Authority
KR
South Korea
Prior art keywords
formulation
sephamandolnaphate
preparation
parenteral use
dry
Prior art date
Application number
KR1019870015751A
Other languages
Korean (ko)
Other versions
KR900000747B1 (en
Inventor
김종국
황성주
임준창
Original Assignee
한치운
주식회사 삼천리제약
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한치운, 주식회사 삼천리제약 filed Critical 한치운
Priority to KR1019870015751A priority Critical patent/KR900000747B1/en
Publication of KR890009405A publication Critical patent/KR890009405A/en
Application granted granted Critical
Publication of KR900000747B1 publication Critical patent/KR900000747B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

내용 없음No content

Description

비경구용 세파만돌나페이트 제제의 제조방법Preparation of Sephamandolnaphate Formulation for Parenteral Use

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

제1도는 세파만돌 나페이트 1몰당 탄산나트륨 0.3몰, 호박산 나트륨 0.5몰, 아스콜빈산 나트륨 0.3몰을 각각 혼합한 조성물의 10% 수용액을 제조하여, 실온(약 13℃)에서 보관할 때 시간경과에 따른 용액의 pH 변화도.FIG. 1 shows a 10% aqueous solution of a composition of 0.3 mol of sodium carbonate, 0.5 mol of sodium succinate, and 0.3 mol of sodium ascorbate per mol of sephamandol naphate, and stored at room temperature (about 13 ° C.). PH gradient of the solution.

Claims (1)

건조상태의 7-(D-2-포밀옥시-2-페닐아세트아미도)-3-(1-메탄-1H-테트라졸-5-일티오메틸)-3-세펨-4-카복실산 나트륨염(세파만돌 나페이트) 1몰당 호박산나트륨염 0.3-1몰의 비율로 조성됨을특징으로 하는, 건조상태의 비경구용 세파만돌 나페이트 제제의 제조방법.Dry 7- (D-2-formyloxy-2-phenylacetamido) -3- (1-methane-1H-tetrazol-5-ylthiomethyl) -3-cepem-4-carboxylic acid sodium salt ( Sephamandol naphate) A method for producing a dry parenteral cephamandol naphate formulation, characterized in that it is formulated at a ratio of 0.3-1 mole of sodium succinate salt per mole. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019870015751A 1987-12-31 1987-12-31 Method for preparing parenteral Sephamandol Naphate formulation KR900000747B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019870015751A KR900000747B1 (en) 1987-12-31 1987-12-31 Method for preparing parenteral Sephamandol Naphate formulation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019870015751A KR900000747B1 (en) 1987-12-31 1987-12-31 Method for preparing parenteral Sephamandol Naphate formulation

Publications (2)

Publication Number Publication Date
KR890009405A true KR890009405A (en) 1989-08-01
KR900000747B1 KR900000747B1 (en) 1990-02-15

Family

ID=19267993

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019870015751A KR900000747B1 (en) 1987-12-31 1987-12-31 Method for preparing parenteral Sephamandol Naphate formulation

Country Status (1)

Country Link
KR (1) KR900000747B1 (en)

Also Published As

Publication number Publication date
KR900000747B1 (en) 1990-02-15

Similar Documents

Publication Publication Date Title
KR840005083A (en) Method for preparing amino acid derivatives useful as antihypertensive agents
SE8602404D0 (en) NEW FORMULATION
FI820529L (en) BISPIDINDERIVAT, DERAS FRAMSTAELLNING OCH DESSA INNEHAOLLANDE CEILING MODEL
DK65987A (en) 1,4-BENZOXAZINE DERIVATIVES OR ACID ADDITION SALTS THEREOF, PROCEDURE FOR PREPARING THE COMPOUNDS AND USE OF THE COMPOUNDS
KR830003478A (en) Method for preparing 6-N-propyl-8α-methoxymethyl or methyl mercaptomethyl ergoline derivative
KR860003249A (en) Method for preparing pyoxycamp monohydrate
FI875353A (en) CYTOSTATISKT VERKANDE ANTRACYKLINDERIVAT.
AU578783B2 (en) Pyridopyrimidines, several processes for their preparation and their use as medicaments
KR870003994A (en) Dopamine-β-hydroxylase Inhibitor
NO874540D0 (en) PROCEDURE FOR THE PREPARATION OF Aqueous SOLUTIONS CONTAINING CHROMOGENIC MATERIALS.
KR890009405A (en) Preparation of Sephamandolnaphate Formulation for Parenteral Use
KR870000065A (en) Slightly acidic bath water former
KR830004845A (en) Pharmaceutical preparations
TR23253A (en) USING THE SUELFONOTS AND SUELFUERIC ACID OF THE SUCCESS OF SODIUM SUELFAT, ALKALI SUELFAT OF THE PARAFIN-SULFOXIDATION-REACTION MIX, AND THE SUELFUERIC ACID.
DK146973C (en) STABILIZED, Aqueous FEED CONSERVATION SOLUTION CONTAINING 35-40 PCT'S FORMALIN, ACID AND AS STABILIZER URINE AND METHANOL
DE59006292D1 (en) Aqueous solutions of sodium salts of trimercapto-s-triazine, their preparation and use.
DK420187A (en) OXIRAN-PSEUDOOLIGOSACCHARIDES, THEIR PREPARATION AND USE
JPS5344572A (en) 5-alkoxy-picolic acid, its preparation and hypotensives containing the same
JPS52122387A (en) 7alpha-methoxycephalosporin derivatives and their preparation
ATE87902T1 (en) DERIVATIVES OF 2,2-DIMETHYLCYCLOPROPANECARBONIC ACID.
KR900016226A (en) Method for preparing celldidium sodium
KR880000231A (en) Manufacturing method of balkanized fiber
KR830002737A (en) Method for preparing sulfamethoxazole lysine salt
KR870009662A (en) Preparation method of salt for pickling and food addition with organic acid
DE3873135D1 (en) CATIONIC DIAZACYANINE DYES.

Legal Events

Date Code Title Description
A201 Request for examination
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19871231

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19871231

Comment text: Request for Examination of Application

PG1501 Laying open of application
G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

Comment text: Decision on Publication of Application

Patent event code: PG16051S01I

Patent event date: 19900117

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 19900430

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 19900515

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 19900515

End annual number: 3

Start annual number: 1

PR1001 Payment of annual fee

Payment date: 19920908

Start annual number: 4

End annual number: 6

FPAY Annual fee payment

Payment date: 19951215

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 19951215

Start annual number: 7

End annual number: 9

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee